Terms: = Prostate cancer AND KDM5C, XE169, SMCX, JARID1C, 8242, ENSG00000126012, DXS1272E, MRXSJ, MRXJ, RP11-258C19_2 AND Prognosis
3003 results:
1. CYP7B1 as a Biomarker for prostate cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in prostate cancer Patients-Diamond Study).
Russo GI; Durukan E; Asmundo MG; Lo Giudice A; Salzano S; Cimino S; Rescifina A; Fode M; Abdelhameed AS; Caltabiano R; Broggi G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731981
[TBL] [Abstract] [Full Text] [Related]
2. A cross-sectional study of ERG expression and the relationship with clinicopathological features of prostate cancer in Southwestern Uganda.
Mitala Y; Ssenkumba B; Birungi A; Kiconco R; Mutakooha MM; Atwine R
Diagn Pathol; 2024 May; 19(1):67. PubMed ID: 38730435
[TBL] [Abstract] [Full Text] [Related]
3.
Fan Y; Ge Y; Niu K; Li Y; Qi LW; Zhu H; Ma G
Front Immunol; 2024; 15():1364329. PubMed ID: 38698844
[TBL] [Abstract] [Full Text] [Related]
4. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
[TBL] [Abstract] [Full Text] [Related]
5. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of Treatment Response.
Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
[TBL] [Abstract] [Full Text] [Related]
6. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
7. Mechanism of single-stranded DNA annealing by RAD52-RPA complex.
Liang CC; Greenhough LA; Masino L; Maslen S; Bajrami I; Tuppi M; Skehel M; Taylor IA; West SC
Nature; 2024 May; 629(8012):697-703. PubMed ID: 38658755
[TBL] [Abstract] [Full Text] [Related]
8. [Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of prostate cancer].
Li JC; Zhu XJ; Ye JH; Tan ZH; Cai SH; Deng YL; Chen J; Tian WC; Luo DH; Zhong WD
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1410-1417. PubMed ID: 38644292
[No Abstract] [Full Text] [Related]
9. AAT resistance-related AC007405.2 and AL354989.1 as novel diagnostic and prognostic markers in prostate cancer.
Deng Y; Zhang C; Yu H; Chen G; Peng X; Li Y; Feng Z; Shi W; Bai X; Gou X; Liu N
Aging (Albany NY); 2024 Apr; 16(8):7249-7266. PubMed ID: 38643469
[TBL] [Abstract] [Full Text] [Related]
10. An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Cheng Y; Wu L; Xin J; Ben S; Chen S; Li H; Zhao L; Wang M; Cheng G; Du M
J Transl Med; 2024 Apr; 22(1):366. PubMed ID: 38632662
[TBL] [Abstract] [Full Text] [Related]
11. Excess weight, weight gain, and prostate cancer risk and prognosis: the PROCA-life study.
Støyten M; Knutsen T; Stikbakke E; Agledahl I; Wilsgaard T; Eggen AE; Richardsen E; Giovannucci E; Thune I; Haugnes HS
Acta Oncol; 2024 Apr; 63():154-163. PubMed ID: 38591351
[TBL] [Abstract] [Full Text] [Related]
12. Decoding the tumour-modulatory roles of LIMK2.
Chong ZX; Ho WY; Yeap SK
Life Sci; 2024 Jun; 347():122609. PubMed ID: 38580197
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic significance of tumor suppressor protein p53 in prostate cancer.
Ben Rejeb S; Kouki N; Elfekih S; Cherif I; Khouni H
Tunis Med; 2024 Feb; 102(2):111-115. PubMed ID: 38567478
[TBL] [Abstract] [Full Text] [Related]
14. Primary mucinous adenocarcinoma of the urethra: A contemporary clinicopathologic analysis of 17 patients.
Alrohaibani A; Osunkoya AO
Pathol Res Pract; 2024 Apr; 256():155273. PubMed ID: 38565023
[TBL] [Abstract] [Full Text] [Related]
15. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
[TBL] [Abstract] [Full Text] [Related]
16. Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.
Hemminki K; Zitricky F; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki O
Cancer Med; 2024 Apr; 13(7):e7126. PubMed ID: 38545829
[TBL] [Abstract] [Full Text] [Related]
17. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Mahon KL; Sutherland SI; Lin HM; Stockler MR; Gurney H; Mallesara G; Briscoe K; Marx G; Higano CS; de Bono JS; Chi KN; Clark G; Breit SN; Brown DA; Horvath LG
Prostate; 2024 Jun; 84(8):747-755. PubMed ID: 38544345
[TBL] [Abstract] [Full Text] [Related]
18. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of prostate cancer.
Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
[TBL] [Abstract] [Full Text] [Related]
19. CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
Dwina Y; Zaid LSM; Saraswati M; Rachmadi L; Kekalih A; Rahadiani N; Louisa M; Agustina H; Mochtar CA; Hamid ARAH
Prostate; 2024 Jun; 84(8):738-746. PubMed ID: 38528654
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Patients With prostate cancer: A Systematic Review and Meta-Analysis.
Xiang Q; Liu Y; Xiao J; Ou L; Du J
Am J Mens Health; 2024; 18(2):15579883241234747. PubMed ID: 38514969
[TBL] [Abstract] [Full Text] [Related]
[Next]